CÉSAR EDUARDO FERNANDES
Professor livre-docente e chefe da Clínica Ginecológica da Disciplina de Ginecologia e Obstetrícia da Faculdade de Medicina do ABC
JOEL RENNÓ JR.
Doutor em medicina pela Faculdade de Medicina da Universidade de São Paulo (FMUSP); coordenador do Projeto de Atenção à Saúde Mental da Mulher (Projeto Pró-Mulher) do Instituto de Psiquiatria do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo.
ELIANA AGUIAR PETRI NAHAS
Professora Doutora do Departamento de Ginecologia e Obstetrícia da Faculdade de Medicina de Botucatu – UNESP, São Paulo.
NILSON ROBERTO DE MELO
Professor Livre Docente do Departamento de Obstetrícia e Ginecologia da Faculdade de Medicina da Universidade de São Paulo.
JOSÉ ARNALDO DE SOUZA FERREIRA
Professor Assistente Doutor da Disciplina de Ginecologia e Obstetrícia da Faculdade de Medicina do ABC.
ROGÉRIO BONASSI MACHADO
Professor Adjunto do Departamento de Tocoginecologia da Faculdade de Medicina de Jundiaí.
SÉRGIO PEIXOTO
Professor Titular da Disciplina de Ginecologia e Obstetrícia da Faculdade de Medicina do ABC; Professor Associado do Departamento de Obstetrícia e Ginecologia da Faculdade de Medicina da Universidade de São Paulo.
Abstract:
The women’s androgen insufficiency syndrome (AIS) arises, even nowadays, many debates and clears a lot of controversies. It is known, however, that the plasmatic levels of testosterone gradually decline through the reproductive period. AIS is appraised as a set of clinical symptoms, bioavailability presence diminished of testosterone and normal levels of estrogen. Among the main symptoms that remind the diagnosis are the well-being impairment, dysphoric mood, the fatigue without apparent cause, the sexual desire impairment, the loss of weight and the vasomotor instability in postmenopausal women receiving estrogen. These, however, are potentially attributable to the different etiologies and make it difficult to give the correct diagnosis in the majority of the cases, even though it is reminded, often, in patients who submit to bilateral oophorectomy. The diagnosis of the SIA seems to be essentially clinical, not having the needs of laboratorial dosages for its proof. It shouldn’t indicate the androgenic therapy (AT) in patients without concomitant estrogen therapy. Testosterone is considered the ideal hormone for AT. Patients with suggestive SIA symptoms, excluded other identifiable causes, especially the post-menopauses ones, are candidates to AT. There are no safety data about AT in long stated period users. The transdermal patches, creams and gel seems to be preferable to the oral formulations.
Keywords:Androgen deficiency, androgen therapy, female sexual dysfunction.